KRAS and pancreatic neoplasm: This prevalence of MGMT‐silencing is not negligible in the context of pancreatic cancer, where the only validated actionable biomarkers so far are germline BRCA1‐2/PALB2 (for platinum salts and PARP inhibitors) [4] and KRAS G12C (for direct inhibitors [32]) mutations, which are found in ~5% and ~1% of cases, respectively.